Company Performance Metrics
Franklin P. Bymaster: Co-Founder & Chief Scientific OfficerPast Role: Eli Lilly, Senior Research Scientist
Tom Shea: CFOPast Role: Epirus Biopharmaceuticals, Chief Financial Officer
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs.
EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard
antidepressants including weight gain, sexual dysfunction and cognitive impairment. Euthymics is a private Delaware corporation with headquarters in Cambridge, Massachusetts.
Euthymics is developing products for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and, under a collaboration with the government, alcohol use disorder (AUD).
According to the National Institutes of Health, MDD affects over 15 million American adults. According to the National Institute of Alcohol Abuse and Alcoholism (NIAAA), approximately 18 million Americans have alcohol use disorder (either alcohol dependence or alcohol abuse).
